Major Shareholder Announcement
23 September 2016 - 2:16AM
Company Announcement
- Major shareholder announcement for Genmab
A/S
COPENHAGEN, Denmark, Sept. 22, 2016 (GLOBE NEWSWIRE)
-- Genmab A/S (Nasdaq Copenhagen: GEN) announces under
reference to Section 29 of the Danish Securities Trading Act that
Baillie Gifford & Co has informed us that, as of September 22,
2016, Baillie Gifford & Co has increased their indirect
ownership in Genmab A/S to 3,021,069 shares, which amounts to 5.02%
of the share capital and voting rights in Genmab A/S.
About Genmab Genmab is a publicly traded,
international biotechnology company specializing in the creation
and development of differentiated antibody therapeutics for the
treatment of cancer. Founded in 1999, the company has two
approved antibodies, Arzerra(r) (ofatumumab) for the treatment of
certain chronic lymphocytic leukemia indications and DARZALEX(r)
(daratumumab) for the treatment of heavily pretreated or double
refractory multiple myeloma. Daratumumab is in clinical development
for additional multiple myeloma indications and for non-Hodgkin's
lymphoma. Genmab also has a broad clinical and pre-clinical product
pipeline. Genmab's technology base consists of validated and
proprietary next generation antibody technologies - the DuoBody(r)
platform for generation of bispecific antibodies, and the
HexaBody(r) platform which creates effector function enhanced
antibodies. The company intends to leverage these
technologies to create opportunities for full or co-ownership of
future products. Genmab has alliances with top tier pharmaceutical
and biotechnology companies. For more information visit
www.genmab.com.
Contact:
Rachel Curtis Gravesen, Senior Vice President, Investor Relations
& Communications T: +45 33 44 77 20; M: +45 25 12 62 60;
E: r.gravesen@genmab.com
This Company Announcement contains forward looking statements.
The words "believe", "expect", "anticipate", "intend" and "plan"
and similar expressions identify forward looking statements. Actual
results or performance may differ materially from any future
results or performance expressed or implied by such statements. The
important factors that could cause our actual results or
performance to differ materially include, among others, risks
associated with pre-clinical and clinical development of products,
uncertainties related to the outcome and conduct of clinical trials
including unforeseen safety issues, uncertainties related to
product manufacturing, the lack of market acceptance of our
products, our inability to manage growth, the competitive
environment in relation to our business area and markets, our
inability to attract and retain suitably qualified personnel, the
unenforceability or lack of protection of our patents and
proprietary rights, our relationships with affiliated entities,
changes and developments in technology which may render our
products obsolete, and other factors. For a further discussion of
these risks, please refer to the risk management sections in
Genmab's most recent financial reports, which are available on
www.genmab.com . Genmab does not undertake any obligation to update
or revise forward looking statements in this Company Announcement
nor to confirm such statements in relation to actual results,
unless required by law.
Genmab A/S and its subsidiaries own the following trademarks:
Genmab(r); the Y-shaped Genmab logo(r); Genmab in combination with
the Y-shaped Genmab logo(tm); the DuoBody logo(r); the HexaBody
logo(tm); HuMax(r); HuMax-CD20(r); DuoBody(r); HexaBody(r) and
UniBody(r). Arzerra(r) is a trademark of Novartis AG or its
affiliates. DARZALEX(r) is a trademark of Janssen Biotech, Inc.
Company Announcement no. 44 CVR no. 2102 3884
Genmab A/S Bredgade 34E 1260 Copenhagen K
Denmark
Genesis Healthcare (NYSE:GEN)
Historical Stock Chart
From Apr 2024 to May 2024
Genesis Healthcare (NYSE:GEN)
Historical Stock Chart
From May 2023 to May 2024